5622-36-6

Basic information

• Product Name: METHYL 6-QUINOLINEACETATE
• Synonyms: METHYL 6-QUINOLINEACETATE;Quinolin-6-Yl-Acetic Acid Methyl Ester;Methyl 6-quinolineacetate ,95%;Methyl 2-quinolin-6-ylacetate;6-Quinolineacetic acid methyl ester;Methyl 2-(quinolin-6-yl)
• CAS NO: 5622-36-6
• Molecular Formula: C₁₂H₁₁NO₂
• Molecular Weight: 201.22
• Product Categories: Acids and Derivatives;Heterocycles;pharmacetical
• Mol File: 5622-36-6.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 327.8 °C at 760 mmHg
• Flash Point: 152.1 °C
• Appearance: /
• Density: 1.186 g/cm³
• Vapor Pressure: 0.000197mmHg at 25°C
• Refractive Index: 1.601
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 4.82±0.10(Predicted)
• CAS DataBase Reference: METHYL 6-QUINOLINEACETATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 6-QUINOLINEACETATE(5622-36-6)
• EPA Substance Registry System: METHYL 6-QUINOLINEACETATE(5622-36-6)

Safety Data

• Hazardous Substances Data: 5622-36-6(Hazardous Substances Data)

Usage

Uses

Methyl 2-(Quinolin-6-yl)acetate is a reactuant to prepare triazolopyridazines as tyrosine kinase modulators.

InChI:InChI=1/C12H11NO2/c1-15-12(14)8-9-4-5-11-10(7-9)3-2-6-13-11/h2-7H,8H2,1H3

Upstream product

• 67-56-1 methanol 
• 5622-34-4 6-quinoline acetic acid 
• 1197-55-3 4-aminophenylacetic acid 

Downstream Products

• 943541-37-5 oxo-quinolin-6-ylacetic acid methyl ester 
• 227809-77-0 2-(quinolin-6-yl)ethan-1-ol 
• 1022091-89-9 methyl 2-(3-bromoquinolin-6-yl)acetate 
• 959585-30-9 2-(quinolin-6-yl)propanoic Acid 
• 1452839-82-5 (S)-6-(1-(6-(3,4-difluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline 
• 1022088-98-7 (S)-3-(3-(1-(quinolin-6-yl)ethyl)[1,2,4]triazolo[4,3-b]pyridazin-6-yl)benzonitrile 
• 1452839-83-6 (S)-6-(1-(6-(3-fluoro-4-methoxyphenyl)[1,2,4]triazolo[4,3-b]-pyridazin-3-yl)ethyl)quinoline 
• 1452839-84-7 (S)-6-(1-(6-(4-methoxy-3-methylphenyl)[1,2,4]triazolo[4,3-b]-pyridazin-3-yl)ethyl)quinoline 
• 1452839-85-8 (S)-6-(1-(6-(3-methylphenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-ethyl)quinoline 
• 1452839-86-9 (S)-2-(3-(1-(quinolin-6-yl)ethyl)[1,2,4]triazolo[4,3-b]pyridazin-6-yl)benzonitrile 
• 1452839-88-1 (S)-N-methyl-4-(3-(1-(quinolin-6-yl)ethyl)[1,2,4]triazolo[4,3-b]pyridazin-6-yl)benzamide 
• 1452839-89-2 (S)-6-(1-(6-(4-ethanesulfonylphenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline 
• 1452839-90-5 (S)-6-(1-(6-(4-methanesulfonylphenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline 
• 959585-29-6 methyl 2-(quinolin-6-yl)propanoate 

Relevant articles and documents

Discovery of Potent, Selective Triazolothiadiazole-Containing c-Met Inhibitors

Herein, we report a novel series of highly potent and selective triazolothiadiazole c-Met inhibitors. Starting with molecule 5, we have applied structure-based drug design principles to identify the triazolothiadiazole ring system. We successfully replaced the metabolically unstable phenolic moiety with a quinoline group. Further optimization around the 5,6 bicyclic moiety led to the identification of 21. Compound 21 suffered from PDE3 selectivity issues and subsequent, structurally informed design led to the discovery of compound 23. Compound 23 has exquisite kinase selectivity, excellent potency, favorable ADME profile, and showed dose-dependent antitumor efficacy in a SNU-5 gastric cancer xenograft model.

COMPOUNDS AND METHODS

The present invention relates to novel retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORy.

A TRIAZOLOTHIADIAZOLE INHIBITOR OF C-MET PROTEIN KINASE

The present invention relates to compound (1), which is useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising Compound (1) and methods of using the compositions in the treatment of proliferative disorders.